Fohtung Raymond B, Novak Eric, Rich Michael W
Department of Medicine, School of Medicine, Washington University, Saint Louis, Missouri.
J Am Geriatr Soc. 2017 Nov;65(11):2405-2412. doi: 10.1111/jgs.15058. Epub 2017 Aug 21.
To determine the effect of new oral anticoagulants (NOACs) on prescribing practices in older adults with atrial fibrillation (AF).
Retrospective observational cohort study.
Academic medical center in St. Louis, Missouri.
Individuals aged 75 and older with AF admitted to the hospital from October 2010 through September 2015 (N = 6,568, 50% female, 15% non-white).
Information on NOACs and warfarin prescribed at discharge was obtained from hospital discharge summaries, and linear regression was used to examine quarterly trends in their use. Multivariable logistic regression was used to assess independent predictors of anticoagulant use.
NOAC use increased over time (correlation coefficient (r) = 0.87, P < .001), warfarin use did not change (r = -0.16, P = .50), and overall anticoagulant use (NOACs and warfarin) increased (r = 0.68, P = .001). NOAC use increased over time in all age groups (75-79, 80-84, 85-89) except aged 90 and older, but increasing age attenuated the rate of NOAC uptake. There was no consistent relationship between age and warfarin or overall anticoagulant use, except that individuals aged 90 and older had consistently lower use. Overall, fewer than 45% of participants were prescribed an anticoagulant. In multivariable analysis, younger age, white race, female sex, higher hemoglobin, higher creatinine clearance, being on a medical service, hypertension, stroke or transient ischemic attack, no history of intracranial hemorrhage, and a modified HAS-BLED score of less than 3 increased the likelihood of receiving NOACs.
Prescription of anticoagulants for AF increased in older adults primarily because of an increase in the use of NOACs. Nonetheless, fewer than 45% of participants were prescribed an anticoagulant. Additional research is needed to optimize prescribing practices for older adults with AF.
确定新型口服抗凝药(NOACs)对老年心房颤动(AF)患者处方行为的影响。
回顾性观察队列研究。
密苏里州圣路易斯的学术医疗中心。
2010年10月至2015年9月期间入院的75岁及以上的AF患者(N = 6568,50%为女性,15%为非白人)。
出院时开具的NOACs和华法林的信息从医院出院小结中获取,并使用线性回归分析其使用的季度趋势。多变量逻辑回归用于评估抗凝剂使用的独立预测因素。
NOACs的使用随时间增加(相关系数(r)= 0.87,P < .001),华法林的使用没有变化(r = -0.16,P = .50),总体抗凝剂使用(NOACs和华法林)增加(r = 0.68,P = .001)。除90岁及以上年龄组外,所有年龄组(75 - 79岁、80 - 84岁、85 - 89岁)的NOACs使用均随时间增加,但年龄增长会减弱NOACs的采用率。年龄与华法林或总体抗凝剂使用之间没有一致的关系,除了90岁及以上的个体使用量一直较低。总体而言,不到45%的参与者被开具了抗凝剂。在多变量分析中,年龄较小、白人种族、女性、血红蛋白较高、肌酐清除率较高、在医疗科室、患有高血压、中风或短暂性脑缺血发作、无颅内出血病史以及改良HAS - BLED评分小于3会增加接受NOACs的可能性。
老年AF患者抗凝剂处方的增加主要是由于NOACs使用的增加。尽管如此,不到45%的参与者被开具了抗凝剂。需要进一步研究以优化老年AF患者的处方行为。